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CI	 	 	 Confidence	Interval	
CO2	 	 	 Carbon	dioxide	
DAMPs	 	 Damage-associated	molecular	patterns		
DCLHb		 	 Diaspirin	cross-linked	haemoglobin	
DCR	 	 	 Damage	control	resuscitation		
ED	 	 	 Emergency	department	
ELISA	 	 	 Enzyme-linked	immunosorbent	assays	
EoT	 	 	 Endotheliopathy	of	trauma	
EPO	 	 	 Erythropoietin	
FAST	 	 	 Focused	assessment	with	sonography	in	trauma	
FCD		 	 	 Functional	capillary	density	
FFP	 	 	 Fresh	frozen	plasma	
GCS	 	 	 Glasgow	coma	scale	
Hb	 	 	 Haemoglobin	
HBOC	 	 	 Haemoglobin-based	oxygen	carrier	
HC	 	 	 Healthy	control	
HES	 	 	 Hydroxyl-ethyl	starch	
HSA	 	 	 Human	serum	albumin	
HTS	 	 	 Hypertonic	saline	
HVM	 	 	 Handheld	video-microscopy	
ICC	 	 	 Intra-class	correlation	coefficient	
ICU	 	 	 Intensive	care	unit	
IDF	 	 	 Incident	dark	field	
IED	 	 	 Improvised	explosive	device	
IQR	 	 	 Interquartile	range	
ISS	 	 	 Injury	severity	score	
IVM		 	 	 Intravital	microscopy	
LDF	 	 	 Laser	doppler	flowmetry	
LR	 	 	 Ringer’s	lactate	
LSCI	 	 	 Laser	speckle	contrast	imaging	
LVM	 	 	 Low-viscosity	high-mannuronic	acid	
MAP	 	 	 Mean	arterial	pressure	
MetRBC	 	 Methaemoglobin	red	blood	cells	
		 xi	
MFI	 	 	 Microcirculatory	flow	index		
MHI	 	 	 Microcirculatory	heterogeneity	index	
MODS	 	 	 Multiple	organ	dysfunction	syndrome	
MW	 	 	 Molecular	weight	
NETs	 	 	 Neutrophil	extracellular	traps	
NS	 	 	 Normal	saline	
OPS		 	 	 Orthogonal	polarization	spectral	imaging	
OxyRBC	 	 Oxygen-carrying	red	blood	cells	




POEM	 		 	 Point-of-care	microcirculation	
PPV	 	 	 Proportion	of	perfused	vessels	
PVD	 	 	 Perfused	vessel	density	
PRBCs	 	 	 Packed	red	blood	cells	
PRISMA	 	 Preferred	reporting	items	for	systematic	reviews	and	meta-analyses	
RBCs	 	 	 Red	blood	cells	
REC	 	 	 Research	ethics	committee	
SBP	 	 	 Systolic	blood	pressure	
SD	 	 	 Standard	deviation	
SDF	 	 	 Sidestream	dark	field	
SOFA	 	 	 Sequential	Organ	Failure	Assessment	
SPS	 	 	 Serum	protein	solution	
STROBE	 Strengthening	the	reporting	of	observational	studies	in	epidemiology	
SYRCLE	 	 Systematic	review	centre	for	laboratory	animal	experimentation	
THS	 	 	 Traumatic	haemorrhagic	shock	
TIC	 	 	 Trauma	induced	coagulopathy	
TVD		 	 	 Total	vessel	density	








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Age,	years	 33	(24–53)	 38	(24–56)	 25	(23	–	44)	 0.343	
Sex,	male	 75	(85)	 61	(86)	 14	(82)	 0.993	
Mechanism	of	injury	 	 	 	 	
									Blunt	 69	(78)	 60	(85)	 9	(53)	 0.008*	
									Penetrating	 19	(22)	 11	(15)	 8	(47)	 	
Injury	Severity	Score	 23	(12–36)	 24	(14–36)	 16	(9–29)	 0.267	
Pre-hospital	parameters	 	 	 	 	
									Heart	rate,	min-1		 100	(84–110)	 100	(80–118)	 99	(85–108)	 0.686	
									SBP,	mmHg	 121	(96–141)	 118	(96–140)	 127	(118–143)	 0.364	
									Respiratory	rate,	min-1	 20	(16–25)	 20	(16–25)	 18	(13–20)	 0.115	
Physiological	parameters	in	ED		 	 	 	 	
									Lowest	SBP,	mmHg	 115	(99–124)	 114	(99–124)	 119	(102–124)	 0.666	
									Heart	rate,	min-1	 88	(76–99)	 87	(75–99)	 89	(78–103)	 0.629	
									Glasgow	Coma	Scale	 13	(5–15)	 13	(4–15)	 15	(10–15)	 0.150	
									Plasma	lactate,	mmol/l	 4.1	(2.5–6.5)	 4.2	(2.7–6.7)	 3.5	(2.0–5.5)	 0.259	















Syndecan-1	 30	(20–44)	 59	(39	–	140)***	 53	(28	–	150)*	














































Age,	years	 39	(25–63)	 36	(24–45)	 25	(23–48)	 0.417	
Sex,	male	 42	(84)	 16	(89)	 9	(82)	 0.974	
Mechanism	of	injury	 	 	 	 	
									Blunt	 39	(78)	 17	(94)	 7	(64)	 0.729	
									Penetrating	 11	(22)	 1	(6)	 4	(36)	 	
Injury	Severity	Score	 25	(15–38)	 29	(16–38)	 17	(9–29)	 0.230	
Physiological	parameters	in	ED		 	 	 	 	
									Lowest	SBP,	mmHg	 113	(95–122)	 119	(105–129)	 122	(106–134)	 0.030*	
									Heart	rate,	min-1	 87	(80–99)	 93	(81–104)	 88	(76–104)	 0.627	
									Glasgow	Coma	Scale	 13	(3–14)	 12	(6–14)	 15	(11–15)	 0.083	
									Plasma	lactate,	mmol/l	 4.8	(3.0–7.2)	 3.7	(2.5–6.4)	 2.4	(1.3–4.6)	 0.037*	
									Base	deficit,	mmol/l	 -4	(-8	–	-2)	 -3	(-6	–	-1)	 -2	(-3	–	0)	 0.023*	
Blood	product	requirement	 	 	 	 	
									All	patients	transfused	 19	(38)	 0	(0)	 1	(10)	 0.003**	
									Patients	given	RBCs	 19	(38)	 0	(0)	 1	(10)	 0.003**	






































































































































































































































































































































































































































































































































































































































































Age,	mean	(SD)	 41	(19)	 41	(20)	 40	(18)	 0.816	
Male,	N	(%)	 108	(87)	 90	(86)	 16	(94)	 0.466	
BMI,	median	(IQR)	 25	(23–28)	 25	(23–28)	 25	(22–29)	 0.891	
Smoker,	N	(%)	 55	(45)	 47	(45)	 8	(47)	 >0.999	
Alcohol	intoxication,	N	(%)	 19	(16)	 19	(18)	 0	(0)	 0.071	
Co-morbidities	 	 	 	 	
								N	(%)	 26	(21)	 23	(22)	 3	(18)	 >0.999	
								CCI,	median	(range)	 0	(0–5)	 0	(0–5)	 0	(0–4)	 0.814	
ISS,	median	(IQR)	 25	(12–34)	 24	(10–36)	 27	(17–34)	 0.446	
Injury	mechanism,	N	(%)	 	 	 	 	
								Blunt	 101	(81)	 86	(82)	 13	(76)	 0.738	
								Penetrating	 23	(19)	 19	(18)	 4	(24)	 	
GCS,	median	(IQR)	 12	(4–15)	 13	(4–15)	 9	(3–14)	 0.232	
Lactate	(mmol/l),	median	(IQR)	 3.7	(2.5–6.4)	 3.5	(2.5–6.3)	 6.0	(3.6–10.2)	 0.071	
SBP	(mmHg),	median	(IQR)	 111	(97–122)	 114	(99–124)	 91	(61–108)	 0.0002*	
HR	(min-1),	median	(IQR)	 89	(79–100)	 87	(76–99)	 108	(98–118)	 0.0004*	
INR,	median	(IQR)	 1.1	(1.0–1.2)	 1.1	(1.0–1.2)	 1.2	(1.1–1.2)	 0.020*	
PTT	ratio,	median	(IQR)	 0.9	(0.8–1.0)	 0.9	(0.8–0.9)	 0.9	(0.9–1.1)	 0.020*	
Outcomes	 	 	 	 	
								Hospital-free	days,	median	(IQR)	 6	(0–20)		 8	(0–20)	 0	(0–5)	 0.097	
								ICU-free	days,	median	(IQR)		 20	(8–29)	 22	(10–29)	 8	(0–18)	 0.003*	
								Mortality,	n	(%)	 19	(16)	 16	(15)	 3	(18)	 0.728	



























Age,	mean	(SD)	 41	(19)	 43	(21)	 41	(19)	 0.503	
Male,	n	(%)	 108	(87)	 27	(87)	 79	(87)	 >0.999	
ISS,	median	(IQR)	 25	(12–34)	 27	(16–43)	 23	(10–30)	 0.061	
Injury	mechanism,	n	(%)	 	 	 	 	
								Blunt	 101	(81)	 23	(74)	 76	(84)	
0.290	
								Penetrating	 23	(19)	 8	(26)	 15	(16)	
GCS,	median	(IQR)	 12	(4–15)	 10	(3–14)	 13	(4–15)	 0.133	
Lactate	(mmol/l),	median	(IQR)	 3.7	(2.5–6.4)	 6.2	(4.0–9.5)	 3.3	(2.3–5.1)	 <0.0001*	
SBP	(mmHg),	median	(IQR)	 111	(97–122)	 93	(69–109)	 116	(103–124)	 <0.0001*	



























cfDNA	 SD-1	 TM	 	 cfDNA	 SD-1	 TM	
	 	 	 	 	 	 	 	
Age	
R2	 0.006	 0.036	 <0.0001	 	 <0.0001	 0.001	 0.005	
p-value	 0.432	 0.055	 0.969	 	 0.833	 0.778	 0.472	
	 	 	 	 	 	 	 	 	
GCS	
R2	 0.032	 0.011	 0.003	 	 0.051	 0.008	 0.015	
p-value	 0.069	 0.297	 0.613	 	 0.016*	 0.356	 0.197	
	 	 	 	 	 	 	 	 	
Lactate	
R2	 0.006	 0.084	 0.017	 	 0.032	 0.198	 0.094	
p-value	 0.455	 0.004*	 0.201	 	 0.064	 <0.0001*	 0.001*	
	 	 	 	 	 	 	 	 	
SBP	
R2	 0.014	 0.040	 <0.0001	 	 0.031	 0.100	 0.027	
p-value	 0.242	 0.045*	 0.905	 	 0.063	 0.001*	 0.085	
	 	 	 	 	 	 	 	 	
HR	
R2	 <0.0001	 0.003	 0.001	 	 0.018	 0.027	 <0.0001	
p-value	 0.913	 0.579	 0.806	 	 0.16	 0.082	 0.898	
	 	 	 	 	 	 	 	 	
ISS	
R2	 0.098	 0.011	 0.001	 	 0.086	 0.002	 0.029	
p-value	 0.002*	 0.314	 0.809	 	 0.002*	 0.679	 0.081	




























































Pre-hospital	biomarkers,	ng/ml	 	 	 	
													cfDNA	 558	(384–956)	 817	(422–2442)	 0.132	
													Syndecan-1	 49	(35–118)	 59	(33–136)	 0.700	
													Thrombomodulin	 4.3	(3.4–6.2)		 4.7	(3.7–6.3)	 0.508	
1-16h	biomarkers,	ng/ml	 	 	 	
													cfDNA	 411	(233–1141)	 457	(368–609)	 0.231	
													Syndecan-1	 65	(37–197)	 46	(26–111)	 0.110	













Pre-hospital	biomarkers,	ng/ml	 	 	 	
													cfDNA	 828	(379–3174)		 645	(410–1839)	 0.501	
													Syndecan-1	 109	(35–281)	 50	(34–118)	 0.095	
													Thrombomodulin	 5.7	(3.5–7.1)	 4.4	(3.6–5.9)	 0.248	
1-16h	biomarkers,	ng/ml	 	 	 	
													cfDNA	 466	(299–1790)	 433	(346–570)	 0.191	
													Syndecan-1	 107	(43–256)	 43	(25–89)	 0.0005*	






















Biomarker	 INR	 p-value	 PTT	ratio	 p-value	
Pre-hospital	biomarkers	 	 	 	 	
													cfDNA	 0.195	(0.00–0.380)	 0.048*	 0.000	(-0.218–0.220)		 0.993	
													Syndecan-1	 0.208	(0.01–0.392)	 0.036*	 0.338	(0.125–0.521)	 0.002*	
													Thrombomodulin	 0.119	(-0.084–0.311)	 0.119	 0.195	(-0.029–0.399)	 0.078	
1-16h	biomarkers	 	 	 	 	
													cfDNA	 0.054	(-0.157–0.259)	 0.607	 0.222	(0.018–0.407)	 0.028*	
													Syndecan-1	 0.243	(0.053–0.415)	 0.010*	 0.428	(0.244–0.582)	 <0.0001*	



























































Biomarker	 Hospital-free	days	 p-value	 ICU-free	days	 p-value	
Pre-hospital	biomarkers	 	 	 	 	
									cfDNA	 -0.390	(-0.546	–	-0.207)		 <0.0001*	 -0.385	(-0.542	–	-0.201)	 <0.0001*	
									Syndecan-1	 -0.217	(-0.399	–	-0.017)	 0.029*	 -0.187	(-0.373	–	0.014)	 0.060	
									Thrombomodulin	 -0.140	(-0.331	–	0.062)	 0.161	 -0.130	(-0.321	–	0.072)	 0.194	
1-16h	biomarkers	 	 	 	 	
									cfDNA	 -0.331	(-0.490	–	-0.150)		 0.0003*	 -0.334	(-0.493	–	-0.154)		 0.0003*	
									Syndecan-1	 -0.224	(-0.399	–	-0.034)	 0.018*	 -0.207	(-0.384	–	-0.016)		 0.029*	







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Species	 Animals		 Studies	 Weight	range	 Awake,	%	 References	
Rat	 1149	 31	 120–460	g	 0	 22-24,	35,	40-42,	46,	48,	
50,	51,	54-57,	64,	68,	
72-77,	81-83,	88-92	
Hamster	 518	 26	 40–75	g	 100	 25-34,	47,	49,	52,	60,	62,	
63,	65,	70,	71,	78-80,	
84-87	
Rabbit	 94	 3	 0.8–3.5	kg		 0	 53,	59,	61	
Pig	 74	 4	 7–45	kg	 0	 43-45,	58	
Mouse	 68	 2	 25–30	g	 0	 66,	67	
Dog	 56	 5	 22–35	kg		 0	 36-39,	69	





























































































































88,	89	 	 40	 	 	
Cremaster	 5	 66,	67,	73,	
75,	76	





88,	89	 	 	 	 	
Conjunctiva	 4	 36-39	 	 	 	 	 	
Sublingual	 5	 	 	 43,	44,	58	 45,	58	 	 	
Kidney	 5	 41	 88,	89	 	 46,	56	 	 	
Pancreas	 2	 82,	83	 	 	 	 	 	




1	 90	 	 	 	 	 	
Buccal	
mucosa	
1	 	 	 69	 	 	 	
Ear	
chamber	
1	 53	 	 	 	 	 	














Torres	2013	 ✔	 ✔	 ✔	 	 ✔	 ✔	
Kozar	2011	 ✔	 ✔	 ✔	 	 ✔	 	
Zhao	2009,	Wu	2015(b)	 ✔	 ✔	 	 	 ✔	 ✔	
Wu	2015(a)	 ✔	 ✔	 	 	 ✔	 	
Paxian	2003	 ✔	 	 ✔	 ✔	 ✔	 ✔	
Von	Dobschuetz	1999	 ✔	 	 ✔	 ✔	 	 ✔	
Kubulus	2009	 ✔	 	 ✔	 ✔	 	 	
Paes-da-Silva	2003	 ✔	 	 ✔	 	 ✔	 ✔	
Ni	2013,	Torres	2014	 ✔	 	 ✔	 	 ✔	 	
Torres	2015(a),	Zakaria	
2006	
✔	 	 ✔	 	 ✔	 	
Bauer	1993,	Pascual	2001,	
Vajda	2004,	Vollmar	1994	
✔	 	 	 	 ✔	 ✔	
Bauer	1995,	Cabrales	
2007(b),	Maier	2004	
✔	 	 	 	 	 ✔	
Gulati	1998	 ✔	 	 	 ✔	 ✔	 	
Pascual	2002,	Yada-Langui	
2004	
✔	 	 	 	 ✔	 	
Bi	2004	 	 ✔	 ✔	 ✔	 	 ✔	
Cabrales	2004,	Cabrales	
2005(b),	Wettstein	2006	
	 ✔	 	 	 	 ✔	
Cheung	2001,	Ortiz	2014,	
Wettstein	2004(b)	
	 	 ✔	 ✔	 	 	
Cheung	2006,	Cheung	
2007,	Kerger	1997	




	 	 ✔	 ✔	 	 ✔	
Casali	2002,	Kao	2010,	
Torres	2015(b)	
	 	 ✔	 	 ✔	 	
Cabrales	2007(c),	Sakai	
1999,	Scalia	1990	
	 	 ✔	 	 	 ✔	
Cabrales	2007(a),	Villela	
2009	
	 	 ✔	 	 	 	
Peruski	2014	 	 	 	 ✔	 	 	
Kumar	1997	 	 	 	 ✔	 ✔	 	





	 	 	 ✔	 	 ✔	



















































































































Bauer	 1993	 	 *	 	 *	 	 	 2	
Bauer	 1995	 *	 *	 	 *	 	 	 3	
Bi	 2004	 *	 *	 	 	 *	 	 3	
Botzlar	 1996	 	 *	 	 	 	 	 1	
Cabrales	 2004	 *	 *	 	 	 	 	 2	
Cabrales	 2005	(a)	 *	 *	 	 	 	 	 2	
Cabrales	 2005	(b)	 *	 *	 	 	 	 	 2	
Cabrales	 2007	(a)	 *	 *	 	 	 *	 	 3	
Cabrales		 2007	(b)	 *	 *	 	 	 *	 	 3	
Cabrales		 2007	(c)	 *	 *	 	 	 *	 	 3	
Cabrales	 2008	(a)	 *	 *	 	 	 *	 	 3	
Cabrales	 2008	(b)	 *	 *	 	 	 *	 	 3	
Cabrales		 2009	 *	 *	 	 	 *	 	 3	
Casali	 2002	 	 	 	 	 	 	 0	
Cheung	 2001	 *	 *	 	 	 *	 	 3	
Cheung	 2004	 *	 *	 	 	 	 	 2	
Cheung	 2006	 *	 *	 	 	 	 	 2	
Cheung	 2007	 *	 *	 	 	 *	 	 3	
Corso	 1999	 	 *	 	 	 	 	 1	
Cryer		 2005	 	 *	 	 	 	 	 1	
Gierer	 2004	 	 *	 	 	 	 	 1	
Gonzalez	 2012	 *	 	 	 	 	 	 1	
Gonzalez	 2016	 *	 *	 	 *	 	 	 3	
Guerci	 2014	 *	 *	 	 	 *	 	 3	
Gulati	 1998	 	 *	 	 	 	 	 1	
Hermann	 2007	 *	 *	 	 	 	 	 2	
Horstick	 2002	 *	 *	 	 	 	 	 2	
Hungerer		 2006	 *	 *	 	 	 	 	 2	
Kao		 2010	 *	 *	 	 	 *	 	 3	
Kao	 2011	 *	 	 	 	 	 	 1	
Kerger		 1997	 	 *	 	 	 *	 	 2	
Komori	 2005	 	 *	 	 	 	 	 1	
Kozar	 2011	 	 *	 	 	 	 	 1	
Kubulus	 2009	 *	 *	 	 *	 	 	 2	
Kumar	 1997	 	 *	 	 	 	 	 1	
Maier		 2004	 *	 	 	 *	 	 	 2	
Maier		 2009	 *	 *	 	 *	 	 	 3	
Mazzoni	 1990	 *	 *	 	 	 *	 	 3	
Messmer		 2012	 *	 *	 	 	 *	 	 3	
Ni		 2013	 *	 	 	 	 	 	 1	
Nolte	 1997	 *	 *	 	 	 	 	 2	
Ortiz	 2014	 *	 *	 	 	 *	 	 3	
Paes-da-Silva	 2003	 *	 *	 	 	 	 	 2	
Palmer	 2011	 *	 *	 	 	 *	 	 3	
Pascual	 2001	 *	 *	 	 *	 	 	 3	
Pascual	 2002	 *	 *	 *	 *	 	 	 4	
Paxian	 2003	 	 *	 	 	 	 	 1	
Peruski	 2014	 *	 *	 	 *	 	 	 3	
Sakai	 1999	 	 *	 *	 	 *	 	 3	
Sakai	 2002	 	 *	 *	 	 	 	 2	
Scalia	 1990	 	 *	 	 	 	 	 1	

















































































Torres	 2014	 *	 *	 	 	 *	 	 3	
Torres	 2015	(a)	 	 *	 	 	 	 	 1	
Torres	 2015	(b)	 		 *	 		 		 		 		 1	
Vajda		 2004	 *	 *	 		 		 		 		 2	
Vazquez		 2011	 *	 *	 		 		 *	 		 3	
Villela	 2009	 *	 *	 		 		 *	 		 3	
Villela	 2011	 *	 *	 		 		 *	 		 3	
Vollmar	 1994	 *	 *	 		 *	 		 		 3	
Vollmar	 1996	 *	 *	 		 		 		 		 2	
von	Dobschuetz		 1999	 *	 *	 		 		 		 		 2	
Wettstein	 2003	 *	 *	 		 		 *	 		 3	
Wettstein		 2004	(a)	 		 *	 		 		 		 		 1	
Wettstein	 2004	(b)	 *	 *	 		 		 		 		 2	
Wettstein	 2006	 		 *	 		 		 *	 		 2	
Wu	 2015	(a)	 *	 *	 		 		 		 		 2	
Wu	 2015	(b)	 *	 *	 		 		 		 		 2	
Yada-Langui	 2004	 *	 		 		 		 		 		 1	
Zakaria		 2006	 *	 *	 		 		 		 		 2	



















































































































































Bauer	 1993	 	 	 *	 	 	 	 *	 *	 	 3	
Bauer	 1995	 	 *	 *	 	 *	 	 *	 *	 	 5	
Bi	 2004	 	 *	 	 *	 	 *	 *	 *	 	 5	
Botzlar	 1996	 	 	 	 	 *	 	 *	 *	 	 3	
Cabrales	 2004	 	 *	 	 	 *	 	 *	 *	 	 4	
Cabrales	 2005	(a)	 	 *	 	 	 	 	 *	 *	 	 3	
Cabrales	 2005	(b)	 	 *	 	 	 *	 	 *	 *	 	 4	
Cabrales	 2007	(a)	 	 *	 	 *	 	 	 *	 *	 	 4	
Cabrales		 2007	(b)	 	 *	 	 *	 *	 	 *	 *	 	 5	
Cabrales		 2007	(c)	 	 *	 	 *	 	 	 *	 *	 	 4	
Cabrales	 2008	(a)	 	 *	 	 *	 *	 	 *	 *	 	 5	
Cabrales	 2008	(b)	 	 *	 	 *	 	 	 *	 *	 	 4	
Cabrales		 2009	 	 *	 	 *	 	 	 *	 *	 	 4	
Casali	 2002	 	 	 	 	 	 	 	 *	 	 1	
Cheung	 2001	 	 *	 	 *	 *	 	 *	 *	 	 5	
Cheung	 2004	 	 *	 	 	 *	 	 *	 *	 	 4	
Cheung	 2006	 	 *	 	 *	 	 	 *	 *	 	 4	
Cheung	 2007	 	 *	 	 *	 	 	 *	 *	 	 4	
Corso	 1999	 	 	 	 *	 *	 	 *	 *	 	 4	
Cryer		 2005	 	 	 	 	 	 	 *	 *	 	 2	
Gierer	 2004	 	 	 	 	 *	 	 *	 *	 	 3	
Gonzalez	 2012	 	 *	 	 	 	 	 	 	 	 1	
Gonzalez	 2016	 	 *	 *	 	 	 	 *	 *	 *	 4	
Guerci	 2014	 	 *	 	 *	 	 	 *	 *	 	 4	
Gulati	 1998	 	 	 	 	 	 *	 *	 *	 	 3	
Hermann	 2007	 	 *	 	 	 	 *	 *	 *	 	 4	
Horstick	 2002	 	 *	 	 *	 	 	 *	 *	 	 4	
Hungerer		 2006	 	 *	 	 	 	 	 *	 *	 	 3	
Kao		 2010	 	 *	 	 *	 	 	 *	 *	 	 4	
Kao	 2011	 	 *	 	 	 	 	 	 	 	 1	
Kerger		 1997	 	 	 	 *	 	 	 *	 *	 	 3	
Komori	 2005	 	 	 	 	 *	 	 *	 *	 	 3	
Kozar	 2011	 	 	 	 	 *	 	 *	 *	 	 3	
Kubulus	 2009	 	 *	 	 	 *	 	 *	 *	 	 4	
Kumar	 1997	 	 	 	 	 *	 	 *	 *	 	 3	
Maier		 2004	 	 *	 *	 	 	 *	 	 *	 	 4	
Maier		 2009	 	 *	 *	 	 	 	 *	 *	 	 4	
Mazzoni	 1990	 *	 *	 	 *	 *	 	 *	 *	 	 6	
Messmer		 2012	 *	 *	 	 *	 	 	 *	 *	 	 5	
Ni		 2013	 	 *	 	 	 *	 	 	 *	 	 3	
Nolte	 1997	 	 *	 	 	 *	 	 *	 *	 	 4	
Ortiz	 2014	 	 *	 	 *	 	 *	 *	 *	 	 5	
Paes-da-Silva	 2003	 	 *	 	 	 *	 	 *	 *	 	 4	
Palmer	 2011	 	 *	 	 *	 	 	 *	 *	 	 4	
Pascual	 2001	 	 *	 *	 	 *	 	 *	 *	 	 5	
Pascual	 2002	 	 *	 *	 	 *	 	 *	 *	 	 5	
Paxian	 2003	 	 	 	 	 *	 *	 *	 *	 	 4	












































































































































Sakai	 1999	 	 	 	 *	 	 	 *	 *	 	 3	
Sakai	 2002	 	 	 	 	 	 *	 *	 *	 	 3	
Scalia	 1990	 	 	 	 	 *	 	 *	 *	 	 3	
Torres	 2013	 	 *	 	 	 *	 	 *	 *	 	 4	
Torres	 2014	 	 *	 	 *	 *	 	 *	 *	 	 5	
Torres	 2015	(a)	 	 	 	 	 *	 	 	 	 	 1	
Torres	 2015	(b)	 	 	 	 	 	 	 *	 	 	 1	
Vajda		 2004	 	 *	 	 	 *	 	 *	 *	 	 4	
Vazquez		 2011	 	 *	 	 *	 	 	 *	 *	 	 4	
Villela	 2009	 	 *	 	 *	 	 *	 *	 *	 	 5	
Villela	 2011	 	 *	 	 *	 	 	 *	 *	 	 4	
Vollmar	 1994	 	 *	 *	 	 *	 	 *	 *	 	 5	
Vollmar	 1996	 	 *	 	 	 	 	 	 *	 	 2	
von	Dobschuetz		 1999	 	 *	 	 	 *	 	 *	 *	 	 4	
Wettstein	 2003	 	 *	 	 *	 	 	 *	 *	 	 4	
Wettstein		 2004	(a)	 	 	 	 	 	 	 *	 *	 	 2	
Wettstein	 2004	(b)	 	 *	 	 	 	 	 *	 *	 	 2	
Wettstein	 2006	 	 	 	 *	 *	 	 *	 *	 	 4	
Wu	 2015	(a)	 	 *	 	 	 *	 	 *	 *	 	 4	
Wu	 2015	(b)	 *	 *	 	 	 *	 	 *	 *	 	 5	
Yada-Langui	 2004	 	 *	 	 	 *	 	 	 *	 	 3	
Zakaria		 2006	 	 *	 	 	 *	 	 *	 *	 	 4	









































































































































































































































































































































































































































































































































































































































































































































































































































































Rat	 IVM	 FFP	 NS	 Glycocalyx	
thickness,	flow	
Plasma	can	restore	
the	endothelial	
glycocalyx	and	flow	
Techniques:	IVM:	intravital	microscopy	
Fluids:	PRBC:	packed	red	blood	cells;	LR:	Ringer's	lactate;	NS:	normal	saline;	HTS:	hypertonic	saline;	HC:	haemorrhage-only	control;	
HES:	hydroxyl-ethyl	starch;	FFP:	fresh	frozen	plasma	
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Although	of	interest	in	the	basic	science	of	endothelial	behaviour,	in	vitro	studies116	
and	those	that	measured	endothelial	relaxation117,	118	and	activity119	were	excluded.	
Similarly,	conformational	changes	in	red	blood	cells	(such	as	deformability	and	fragility99,	
106),	and	the	modulation	of	the	inflammatory	components	of	haemorrhagic	shock120	and	
leucocyte	behaviour48,	81	were	ineligible	for	inclusion.		
Studies	that	only	reported	perfusion	endpoints	(such	as	delivery	of	oxygen)	rather	
than	any	microcirculatory	flow	dynamics	were	also	excluded17,	18.			
	
7.4.	 Discussion	
According	to	the	pre-clinical	available	evidence,	the	most	favourable	properties	of	
resuscitative	fluids	for	the	restoration	of	the	microcirculatory	flow	dynamics	are:	(i)	the	
presence	of	a	haemoglobin	preparation	(HBOC	being	mostly	equivalent	to	whole	blood);	(ii)	
higher	viscosity;	(iii)	higher	oncotic/osmotic	potential,	and	(iv)	having	the	physical	and	
constituent	properties	that	enable	attenuation	of	endothelial-leucocyte	interactions,	
reduced	inflammation	and	endothelial	permeability.	The	evidence	for	these	properties	
comes	from	71	published	pre-clinical	studies	that	have	each	tested	the	basic	scientific	
questions	regarding	physical	properties	of	resuscitation	fluids,	as	well	as	the	influence	of	
their	constituents.	Since	none	have	tested	all	of	these	properties	in	a	single	experiment,	it	is	
only	by	summation	and	consideration	of	all	available	evidence	that	translatable	research	
questions	might	be	considered	for	the	clinical	context.		
After	catastrophic	haemorrhage	whole	blood	is	not	usually	readily	available,	and	
fractionated	parts	of	blood	such	as	PRBCs,	FFP,	and	platelets	are	precious	resources.	
Furthermore,	the	most	appropriate	ratios	of	these	fractions	is	a	matter	of	controversy121.	
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Availability	is	also	not	the	only	limitation,	since	whole	blood	or	components	may	not	be	the	
ideal	fluids	to	deliver	following	haemorrhagic	shock;	some	of	these	pre-clinical	studies	have	
demonstrated	superiority	of	other	fluid	strategies	to	delivery	of	whole	blood.	Regardless	of	
the	type	of	fluid	delivered	in	the	emergency	scenario,	the	priority	is	to	restore	tissue	
perfusion	by	enabling	the	transport	of	oxygen	at	the	microcirculatory	surface.	This	goal	
requires	consideration	of	which	characteristics	of	the	resuscitative	fluid	are	most	important	
for	that	task.	Not	only	should	the	fluid	restore	the	microcirculatory	flow	dynamics,	but	may	
also	contribute	to	the	mitigation	and	repair	of	endothelial	injury	that	has	occurred	following	
haemorrhage.	Restoration	of	the	endothelium	and	endothelial	glycocalyx	and	prevention	of	
leucocyte-endothelial	interactions	may	be	key	for	longer-term	outcomes,	but	such	a	
question	has	not	been	answered	in	animal	models.	All	of	the	individual	fluid	characteristics	
reported	here	provide	a	sound	basis	for	further	clinical	research.		
The	design	of	an	‘ideal’	fluid	for	resuscitation	after	haemorrhagic	shock	appears	to	
depend	on	several	factors	of	importance.	The	careful	balance	of	osmotic	potential	and	
viscosity	in	resuscitative	fluids	appears	to	allow	the	fluid	to	inhibit	endothelial	cell	swelling,	
minimise	shear	stress,	and	keep	the	individual	microcirculatory	segments	open	long	enough	
to	allow	the	exchange	of	oxygen	between	the	circulation	and	the	end	tissues.	Some	studies	
in	this	review	have	reported	that	Hb	preparations	and	red	cells	improve	the	microcirculatory	
function	by	their	osmotic	and	viscous	effect	on	microcirculatory	flow	dynamics	rather	than	
their	oxygen	carrying	capacity.	Reduction	in	cell	swelling	and	maladaptive	endothelial-
leucocyte	interactions	might	lead	to	reduction	in	shunting	of	flow	and	subsequent	systemic	
inflammatory	response.	The	fluid	itself	has	potential	to	deposit	glycoproteins	and	essential	
components	of	the	endothelial	glycocalyx	that	may	enable	the	microcirculation	to	improve	
its	function.	Although	HBOCs	are	thought	to	interfere	with	the	endothelium	derived	relaxing	
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factor	and	NO	system	and	increase	vasoconstriction,	unwanted	oxidative	reactions,	and	
endothelial-leucocyte	interactions,	the	studies	included	in	this	review	appear	to	report	that	
appropriate	modification	of	HBOCs	can	reduce	such	unwanted	effects.		
As	well	as	the	usual	limitations	in	translatability	that	arise	when	attempting	to	apply	
results	of	animal	studies	to	the	clinical	context,	the	studies	included	in	this	review	were	all	
at	risk	of	threats	to	their	validity	according	to	the	most	widely	common	recommendations	
for	animal	studies21.	The	majority	of	studies	were	undertaken	with	rodent	models	rather	
than	large	animals,	which	may	provide	further	issues	for	translatability;	testing	the	same	
research	question	from	a	rodent	study	in	a	large	animal	study	may	result	in	a	different	
answer122.	Furthermore,	all	studies	had	a	potential	risk	of	bias	according	to	the	SYRCLE	tool;	
indeed,	the	majority	of	studies	were	only	assessed	as	positive	in	3	or	fewer	domains	(out	of	
a	possible	10).	In	particular,	the	general	lack	of	blinding	of	investigators	and	outcome	
assessments	mandate	a	cautious	approach	to	their	interpretation.	It	is	not	known	whether	
these	studies	failed	to	fulfil	all	domains	of	the	assessment	tools	due	to	methodological	
deficiencies	or	whether	they	simply	did	not	report	the	relevant	details.	If	further	animal	
studies	are	to	be	conducted	in	this	field,	we	would	recommend	that	the	experimental	
protocols	and	reporting	technique	are	designed	according	to	the	SYRCLE	tool	domains	of	
importance.	This	tool	is	based	on	the	Cochrane	Collaboration’s	Risk	tool	for	assessing	bias	in	
randomised	controlled	trials,	and	should	therefore	be	the	gold	standard	for	animal	studies	
that	hope	to	establish	clinically	sound	hypotheses123.	It	is	also	important	to	note	that	a	
limited	number	of	studies	used	sublingual	video-microscopy,	which	is	the	most	appropriate	
technique	for	human	translatability,	as	discussed	in	previous	chapters.		
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7.4.1.	 Limitations	
Meta-analytical	tests	could	not	be	undertaken	for	the	studies	included	in	this	review	
since	there	were	too	many	permutations	of	animal	model,	intervention,	and	outcome	
measure	to	provide	consistent	grouping	of	studies.	Such	a	feasibility	assessment	was	pre-
defined	in	the	original	review	protocol.	Statistical	heterogeneity	could	not	be	assessed	and	
funnel	plots	could	not	be	used	to	assess	publication	bias.	This	is	a	notable	limitation	since	
significant	results	are	more	likely	to	be	published124,	and	it	is	likely	that	unpublished	and	
unavailable	studies	have	not	been	included	in	the	current	systematic	review.	Nevertheless,	
this	systematic	review	summarises	the	available	published	literature	with	regards	to	
haemorrhagic	shock	resuscitation	in	pre-clinical	models,	and	provides	a	basis	on	which	to	
test	hypotheses	in	the	clinical	context.		
	 There	are	some	clinically	relevant	omissions	in	the	pre-clinical	literature	with	regards	
to	haemorrhagic	shock	resuscitation	and	the	microcirculation.	For	example,	there	were	no	
studies	that	tested	platelets	as	a	resuscitation	fluid.	When	plasma	was	delivered	and	shown	
to	be	superior,	the	exact	constituent	components	of	benefit	have	not	been	identified.	There	
were	also	no	clinically	relevant	long-term	outcomes	analysed.	The	experimental	protocols	
were	not	intended	to	assess	clinically	relevant	outcomes	such	as	24-hour	or	survival	to	
discharge,	organ	failure,	or	complications	of	treatment.	Such	questions	could	only	be	
reliably	tested	in	the	clinical	context.		
	
7.5.	 Conclusion	
Based	on	the	available	pre-clinical	evidence,	the	ideal	resuscitation	fluid	for	
restoration	of	microcirculatory	flow	following	haemorrhagic	shock	is	likely	to	contain	a	
preparation	of	haemoglobin,	favour	higher	oncotic/osmotic	potential	and	viscosity,	protect	
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and	reconstitute	the	endothelium,	and	attenuate	inflammation.	The	latter	two	of	these	are	
in	keeping	with	the	findings	in	Part	1	of	this	thesis,	where	endotheliopathy	was	reported	as	
a	significant	pathological	element	in	the	early	phase	following	trauma.	The	hypotheses	here	
are	derived	from	an	extensive	series	of	pre-clinical	studies	that	have	tested	the	basic	
biological	questions	regarding	the	physical	properties	of	a	wide	range	of	fluids.	Because	of	
the	potential	risk	of	translatability,	further	evaluation	in	clinical	studies	are	warranted	in	
order	to	determine	the	‘ideal’	resuscitative	fluid	to	restore	the	microcirculation	in	humans.	
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8.1.			Summary	of	findings	
In	Part	1	of	this	thesis	I	have	presented	some	novel	findings	based	on	5	hypotheses	
(Table	1.1),	regarding	the	endothelium	and	microcirculation	in	the	context	of	trauma	and	
haemorrhagic	shock.	The	first	of	these	findings	is	that	there	is	an	association	between	the	
endotheliopathy	of	trauma	and	poor	microcirculatory	flow	following	haemorrhagic	trauma,	
which	is	most	prominent	in	the	first	hours	after	injury1.	Secondly,	endotheliopathy	occurs	
just	minutes	after	trauma,	and	is	associated	with	multiple	organ	dysfunction	syndrome2.	
Thirdly,	these	pathological	processes	are	associated	with	the	presence	of	cell-free	DNA	
within	the	circulation,	which	may	play	a	role	in	the	mechanisms	of	microcirculatory	
impairment	following	trauma	and	haemorrhagic	shock3.	Taken	together,	these	findings	may	
partly	contribute	to	the	growing	narrative	of	the	early	pathological	response	to	trauma,	
particularly	in	the	first	minutes	and	hours	after	injury	(Figure	8.1).						
	
Figure	8.1.	Schematic	diagram	of	the	mechanistic	findings	in	Part	1	
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In	Part	2	of	this	thesis,	I	have	presented	some	data	regarding	the	clinical	context	in	
which	the	microcirculatory	derangements	described	in	Part	1	might	be	important,	by	
addressing	a	further	3	broad	hypotheses	(Table	1.1).	I	have	presented	that	microcirculatory	
flow	can	be	assessed	safely	soon	after	arrival	in	the	Emergency	Department4,	and	that	the	
flow	and	heterogeneity	might	be	quantified	at	the	point-of-care5.	It	might	therefore	be	
proposed	that	microcirculatory	monitoring	be	performed	earlier,	and	be	integrated	into	the	
clinical	management	pathway	if	justified	by	further	investigation	(Figure	8.2).		
	
	
Figure	8.2.	Schematic	diagram	of	(a)	the	traditional	approach	to	microcirculatory	
monitoring,	and	(b)	what	might	be	proposed	based	on	the	findings	within	this	thesis.		
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In	anticipation	that	microcirculatory	monitoring	may	one	day	be	used	within	the	
realm	of	clinical	practice,	I	have	further	presented	a	synthesis	all	of	the	available	pre-clinical	
literature	regarding	fluids	and	restoration	of	microcirculatory	flow6,7.	From	these	pre-clinical	
studies,	it	appears	that	the	optimal	fluid	for	this	aim	would	contain	a	preparation	of	
haemoglobin,	favour	higher	oncotic	potential,	higher	viscosity,	and	mitigate	the	
inflammation	and	endotheliopathy	of	trauma.	Further	clinical	investigations	are	required	in	
order	to	determine	whether	the	hypotheses	generated	from	these	pre-clinical	studies	can	
be	supported	in	clinical	practice,	and	may	be	guided	by	the	findings	presented.			
	
8.2.	 Avenues	for	future	research	
	
	 In	the	process	of	investigating	the	hypotheses	within	this	thesis,	several	more	have	
been	generated	that	require	further	clinical	studies	in	order	to	address.	Some	research	
questions	warrant	further	discussion,	and	will	be	briefly	summarised	here.		
	
8.2.1	 Does	endotheliopathy	of	trauma	cause	microcirculatory	dysfunction,	or	vice	versa?	
	 In	Chapters	2	–	4,	we	were	able	to	see	associations	between	cfDNA,	
endotheliopathy,	and	microcirculatory	flow	disruption1-3.	Unfortunately,	within	the	
limitations	of	observational	clinical	studies,	the	precise	causality	could	not	be	demonstrated.	
A	linear	narrative	from	point	of	injury	that	includes	a	timeline	of	these	phenomena	cannot	
be	proven	with	the	current	data,	since	there	was	no	definitive	evidence	of	cause-and-effect.	
Indeed,	it	is	likely	that	a	continuous	timeline	from	one	phenomenon	to	another	is	an	over-
simplification,	since	cfDNA,	endotheliopathy,	and	microcirculatory	failure	are	just	a	few	
elements	in	a	far	greater	and	interconnected	network	of	pathological	processes,	that	
includes	coagulopathy8,	inflammatory	dysfunction,	genomic	activation,	and	subsequent	
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organ	failure9,10.	From	the	data	presented,	a	hypothesis	might	be	proposed	that	injury	leads	
to	the	release	of	cfDNA	as	one	type	of	damage-associated	molecular	pattern	(DAMP),	which	
exacerbates	endotheliopathy,	leading	to	microcirculatory	flow	disruption.	Together,	these	
processes	may	each	make	the	others	worse,	and	may	increase	the	likelihood	of	
coagulopathy8,	inflammatory	dysfunction,	and	increase	the	risk	of	subsequent	organ	failure	
and	death	(Figure	8.3).	The	finding	that	the	microcirculatory	flow	dynamics	mostly	improve	
over	time	for	all	patients,	even	when	biomarkers	of	endotheliopathy	may	remain	elevated	
(Chapter	2)1	remains	unexplained.	It	may	suggest	that	current	ICU	resuscitation	techniques	
are	aimed	at	the	restoration	of	flow	and	perfusion,	but	not	endotheliopathy—which	may	be	
responsible	for	poorer	outcomes,	even	when	flow	is	restored.	Whether	ICU	treatment	
directed	at	both	restoration	of	the	endothelium	and	perfusion	and	flow	would	improve	
patient	outcomes	is	unknown.				
	
	
Figure	8.3.	Schematic	illustration	of	a	hypothesis	for	the	sequence	of	events	after	trauma.		
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	 It	is	also	important	to	note	that	any	proposed	sequence	of	events	would	not	exist	in	
isolation,	but	must	be	taken	in	the	context	of	the	many	other	elements	within	the	
physiological	response	to	trauma.	Finding	the	answers	to	questions	regarding	timescales	
may	be	important	when	planning	treatments	that	might	address	each	pathological	factor.	
The	discovery	that	endotheliopathy	occurs	within	minutes	of	injury	may	have	implications	
for	pre-hospital	resuscitative	care,	with	a	potential	new	therapeutic	target:	the	preservation	
and	reconstitution	of	the	endothelial	glycocalyx.	This	may	be	particularly	important	in	the	
context	that	coagulopathy	of	trauma	may	also	be	a	pre-hospital	phenomenon11.			
	
8.2.2		 Why	are	early	pathological	processes	associated	with	organ	failure	days	later?	
	 In	Chapter	3,	the	failure	to	restore	the	endothelium	within	the	first	hours	of	injury	
was	associated	with	organ	failure	some	days	later2.	In	Chapter	4,	raised	cfDNA	was	
associated	with	poorer	clinical	outcomes	days	later3.	The	full	narrative	that	connects	these	
early	phenomena	with	later	clinical	outcomes	is	not	fully	understood.	It	may	be	the	case	
that	these	early	insults	to	the	physiology	may	have	lasting	effects	on	organs,	and	that	failure	
to	“restore”	homeostasis	may	increase	the	likelihood	of	this	occurrence.	This	hypothesis	
would	be	supported	by	data	shown	in	Chapter	3,	where	patients	who	developed	MODS	
were	less	likely	to	have	restoration	of	the	endothelium	than	those	who	did	not2.	A	return	to	
normal	levels	of	endothelial	biomarkers	on	arrival	in	hospital	was	associated	with	lower	
levels	of	organ	failure.	The	exact	physiological,	biochemical,	and	anatomical	effects	of	early	
endotheliopathy	and	microcirculatory	dysfunction	require	further	investigation.	A	better	
understanding	of	homeostatic	mechanisms	would	allow	insights	into	the	pathophysiology	
and	the	potential	therapeutic	opportunities.	
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8.2.3	 Would	point-of-care	tests	for	cfDNA	or	endotheliopathy	be	useful	in	clinical	
practice?		
	 We	have	seen	in	Chapters	2	–	4	that	both	cfDNA	and	endothelial	biomarkers	might	
be	used	to	predict	clinical	outcomes.	Such	data	may	have	the	potential	to	guide	decisions	
such	as	early	triage,	or	requirement	for	surgery	or	intensive	care.	For	example,	could	the	
presence	of	endotheliopathy	or	raised	cfDNA	be	combined	with	other	physiological	
parameters	in	order	to	improve	the	sensitivity	and	specificity	of	pre-hospital	triage	systems,	
or	the	requirement	for	massive	transfusion?	Point-of-care	lactate	devices	have	already	been	
used	within	the	pre-hospital	environment12,	and	in-hospital	lactate	values	from	arterial	
blood	gas	are	commonplace	during	trauma	care,	but	there	are	no	point-of-care	tests	for	
endotheliopathy	in	clinical	practice.	A	rapid	technique	for	cfDNA	quantification	has	been	
described13,	but	this	has	not	yet	entered	clinical	practice.	A	recent	systematic	review	
reported	a	low	level	of	accuracy	for	current	pre-hospital	triage	systems14.	Could	the	addition	
of	further	biochemical	data	within	the	pre-hospital	period	improve	these	systems?		As	well	
as	for	triage	and	prognosis,	it	is	possible	that	they	may	also	have	some	potential	in	guiding	
treatment.	For	example,	would	early	detection	of	endotheliopathy	in	the	pre-hospital	
environment	favour	a	plasma-first	resuscitation	strategy,	in	order	to	restore	the	endothelial	
glycocalyx?	Such	a	question	would	require	prospective	investigation.					
	
8.2.4.		 Could	cfDNA	levels	be	used	as	a	biomarker	of	injury	severity?	
	 There	have	been	some	criticisms	of	the	utility	and	accuracy	of	the	Injury	Severity	
Score	(ISS),	and	several	variations	have	been	proposed15,16.	Furthermore,	anatomical	injury	
severity	scoring	systems	are	vulnerable	to	inter-user	variability17.	These	scoring	systems	
attempt	to	quantify	the	injury	burden	by	adding	together	scores	from	individual	anatomical	
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areas.	Rather	than	calculating	arbitrary	scores	on	an	ordinal	scale,	it	is	possible	that	the	
concentration	of	cfDNA	within	the	circulation	could	be	a	biomarker	of	injury	burden.	
Although	this	has	not	been	thoroughly	investigated,	it	is	an	appealing	hypothesis,	because	it	
may	offer	an	objective,	continuous	variable	that	quantifies	the	full	burden	of	visible	and	
hidden	tissue	injury.	The	exact	quantities	of	tissue	or	cellular	sources	of	cfDNA	would	need	
to	be	determined.	Further	large-scale	investigations	are	required	to	compare	cfDNA	levels	
to	other	forms	of	injury	severity	scoring	systems,	as	well	as	with	clinical	outcomes.		
	
8.2.5.	 Can	bedside	microcirculatory	monitoring	be	used	for	goal-directed	therapy	for	
shocked	patients?	
	 Handheld	video-microscopy	or	the	detection	of	microcirculatory	flow	disruption	has	
been	used	for	research	purposes	for	decades,	but	has	not	yet	entered	mainstream	clinical	
practice.	Two	of	the	factors	preventing	clinical	use	are	(a)	the	lengthy	and	offline	computer	
analysis;	and	(b)	doubts	about	the	feasibility	of	using	this	technology	at	the	point-of-care,	
for	critically	unwell	patients.	These	two	concerns	have	partly	been	addressed	within	
Chapters	5	and	64,5.	I	have	demonstrated	that	the	technique	can	be	used	safely	within	the	
ED,	even	for	patients	with	haemorrhagic	shock,	and	that	it	is	still	possible	to	capture	high	
quality	videos	for	these	patients.	Whether	access	to	these	extra	data	at	the	bedside	might	
affect	clinical	practice	or	guide	resuscitation	is	unknown,	since	no	interventional	trial	has	
been	conducted.	Although	clinicians	might	be	able	to	grade	the	microcirculation	as	
accurately	as	offline	analysis	(Chapter	6),	this	may	not	be	as	accurate	as	traditional	offline	
analysis,	especially	when	it	comes	to	density	parameters.	This	technique	has	also	not	yet	
been	tested	in	real-time	at	the	patient	bedside,	and	its	clinical	utility	is	unknown.	The	next	
step	would	be	to	design	a	study	that	utilised	the	findings	in	both	Chapters	5	and	6,	so	that	
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clinicians	might	assess	the	microcirculation	at	the	bedside	for	critically	unwell	patients.	At	
time	of	writing,	I	am	an	investigator	in	an	ethically	approved	study	that	has	been	designed	
to	do	exactly	this	(Real	time	clinical	validation	of	the	Point-of-Care	Microcirculation	tool	at	
the	bedside;	REC	reference	17/SC/0274).	Furthermore,	a	prospective	randomised	controlled	
trial	with	bedside	handheld	video-microscopy	compared	to	normal	care	might	test	the	
utility	of	these	extra	data	for	goal-directed	therapy.		
	
8.2.6.	 Which	therapeutic	strategies	are	superior	for	the	restoration	of	the	
microcirculation?		
	 Although	some	hypotheses	were	generated	for	this	question	in	Chapter	7	using	a	
systematic	review	of	all	pre-clinical	literature6,	the	answer	for	humans	is	unknown.	There	is	
uncertainty	regarding	the	optimal	ratios	of	blood	products	that	might	be	ideal	following	
trauma	and	haemorrhage18,	and	whether	there	is	a	place	for	crystalloid	or	colloid	fluids	in	
trauma	care.	More	recently,	whole	blood	transfusion	has	been	reported	to	be	associated	
with	greater	survival	than	fractionated	components19.	Furthermore,	there	is	some	pre-
clinical	evidence	of	a	wide	range	of	non-fluid	therapies	that	might	restore	the	
microcirculation,	such	as	sulodexide20,	tranexamic	acid21,	and polyethylene	oxide22.	If	
randomised	controlled	trials	are	undertaken	in	the	future	to	compare	resuscitation	
strategies	(such	as	component	therapy	versus	whole	blood	for	damage	control	
resuscitation),	data	regarding	microcirculatory	flow	would	be	of	value,	especially	if	those	
data	were	to	be	associated	with	clinical	outcomes.		
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